Humulin Regular (Διαλυτή) Kwikpen (Insulin Human)

Humulin Regular Kwikpen is indicated for the management of blood glucose in patients with diabetes mellitus.

• Initiation of basal insulin therapy in adults diagnosed with type 1 diabetes mellitus to achieve fasting glucose targets.
• Supplemental insulin added to oral antidiabetic agents in type 2 diabetes mellitus when glycemic control remains inadequate.
• Mealtime (prandial) insulin administered shortly before meals to reduce post‑prandial glucose spikes and improve overall A1C.
• Temporary use during insulin‑pump transition periods or when basal insulin dosing requires rapid adjustment.
• Considered for gestational diabetes management when a short‑acting insulin is preferred, under specialist guidance.

• Humulin Regular contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, facilitating translocation of GLUT‑4 transporters to the cell membrane and enhancing glucose uptake. In the liver, it suppresses gluconeogenesis and promotes glycogen synthesis, thereby lowering circulating glucose levels in a dose‑dependent manner.

The most frequently reported adverse reactions to Humulin Regular are related to its pharmacologic action and injection site.

Common

• Hypoglycemia, especially if meals are missed or dosing is excessive.
• Injection‑site pain, redness, or swelling.
• Lipodystrophy or localized tissue thickening with repeated use.
• Mild allergic skin reactions such as rash or itching.
• Weight gain due to increased anabolic activity.
• Transient visual disturbances such as blurred vision during hypoglycemic episodes.

Serious

• Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness).
• Anaphylactic or systemic allergic reactions, including urticaria, angioedema, or bronchospasm.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Edema or fluid retention, particularly in patients with cardiac or renal impairment.

When prescribing Humulin Regular, clinicians and patients should observe several precautions to minimize risks and ensure safe use.

• Adjust dose based on carbohydrate intake, physical activity, and renal or hepatic function.
• Monitor blood glucose frequently, especially when initiating therapy or changing dose.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Avoid use in patients with known hypersensitivity to human insulin or any excipients.
• Consider reduced dosing during pregnancy or lactation only under medical supervision.
• Store pens according to manufacturer instructions; do not use if the solution is discolored.
• Do not share pens between individuals to prevent cross‑contamination.

Humulin Regular may interact with other medicines, affecting glucose control or increasing the risk of adverse events.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which can cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, making detection difficult.
• High‑dose corticosteroids that markedly raise blood glucose, potentially overwhelming insulin effect.
• Thiazide diuretics that may increase blood glucose levels, reducing insulin efficacy.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that also lower glucose and may increase hypoglycemia risk.
• ACE inhibitors or ARBs, which can potentiate insulin’s glucose‑lowering effect.
• Alcohol consumption, which can cause unpredictable glucose fluctuations.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that can affect renal function and alter insulin clearance.